Dan Abrams Co. LLC adequately alleged that Medtronic defrauded the FDA by falsely stating in an application that its devices could be used on the spine below the neck area, the U.S. Court of Appeals for the Ninth Circuit said in a nonprecedential decision partially reviving the suit.
This portion of the suit satisfied the FCA’s materiality requirement because proper device use ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.